NO20032229L - Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer - Google Patents
Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorerInfo
- Publication number
- NO20032229L NO20032229L NO20032229A NO20032229A NO20032229L NO 20032229 L NO20032229 L NO 20032229L NO 20032229 A NO20032229 A NO 20032229A NO 20032229 A NO20032229 A NO 20032229A NO 20032229 L NO20032229 L NO 20032229L
- Authority
- NO
- Norway
- Prior art keywords
- p38kinase
- treating
- methods
- kinase inhibitors
- compounds useful
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24987700P | 2000-11-17 | 2000-11-17 | |
| US31056101P | 2001-08-07 | 2001-08-07 | |
| PCT/US2001/049982 WO2002040486A2 (en) | 2000-11-17 | 2001-11-07 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032229D0 NO20032229D0 (no) | 2003-05-16 |
| NO20032229L true NO20032229L (no) | 2003-07-16 |
Family
ID=26940426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032229A NO20032229L (no) | 2000-11-17 | 2003-05-16 | Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1363910B1 (cs) |
| JP (1) | JP2004522713A (cs) |
| KR (1) | KR100847605B1 (cs) |
| CN (1) | CN1622946A (cs) |
| AR (1) | AR032637A1 (cs) |
| AT (1) | ATE318820T1 (cs) |
| AU (2) | AU2002232760B2 (cs) |
| BG (1) | BG107750A (cs) |
| BR (1) | BR0115446A (cs) |
| CA (1) | CA2429628A1 (cs) |
| CY (1) | CY1105250T1 (cs) |
| CZ (1) | CZ20031370A3 (cs) |
| DE (1) | DE60117607T2 (cs) |
| DK (1) | DK1363910T3 (cs) |
| EE (1) | EE200300227A (cs) |
| ES (1) | ES2259051T3 (cs) |
| GE (1) | GEP20063915B (cs) |
| HR (1) | HRP20030485A2 (cs) |
| HU (1) | HUP0303897A2 (cs) |
| IL (1) | IL155570A0 (cs) |
| IS (1) | IS6816A (cs) |
| MX (1) | MXPA03004290A (cs) |
| MY (1) | MY127066A (cs) |
| NO (1) | NO20032229L (cs) |
| NZ (1) | NZ525334A (cs) |
| PE (1) | PE20020819A1 (cs) |
| PL (1) | PL366376A1 (cs) |
| PT (1) | PT1363910E (cs) |
| SK (1) | SK5402003A3 (cs) |
| WO (1) | WO2002040486A2 (cs) |
| YU (1) | YU37903A (cs) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| JP2004530722A (ja) * | 2001-06-29 | 2004-10-07 | アブ サイエンス | 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法 |
| WO2003002108A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| CA2452368A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
| PT1401416E (pt) | 2001-06-29 | 2007-02-28 | Ab Science | Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii) |
| US7700610B2 (en) | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
| GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| DK1474395T3 (da) | 2002-02-12 | 2008-02-11 | Smithkline Beecham Corp | Nicotinamidderivater, der er nyttige som p38-inhibitorer |
| OA12771A (en) | 2002-02-14 | 2006-07-04 | Pharmacia Corp | Substituted pyridinones as modulators of P38 map kinase. |
| US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| WO2003091229A1 (en) | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| PL219736B1 (pl) | 2002-04-23 | 2015-07-31 | Bristol Myers Squibb Co | Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie |
| US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US6933386B2 (en) * | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| NZ541232A (en) * | 2003-01-09 | 2008-02-29 | Astellas Pharma Inc | Pyrrolopyridazine derivatives |
| AU2004212435A1 (en) * | 2003-02-05 | 2004-08-26 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine kinase inhibitors |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| ES2332135T3 (es) | 2003-06-03 | 2010-01-27 | Novartis Ag | Inhibidores p-38 basados en heterociclo de 5 miembros. |
| TWI449696B (zh) | 2003-06-26 | 2014-08-21 | Novartis Ag | 以５員雜環為主之ｐ３８激酶抑制劑 |
| EP1990338B1 (en) | 2003-07-25 | 2010-09-22 | Novartis AG | Biphenylcyclopropylamides as p-38 Kinase inhibitors |
| GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| BRPI0418112A (pt) * | 2003-12-23 | 2007-04-17 | Novartis Ag | inibidores de p-38 quinase bicìclico heterocìclicos |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| DE602005023504D1 (de) * | 2004-10-26 | 2010-10-21 | Novartis Ag | Pyrroloä1,2-düä1,2-4ütriazin als inhibitoren von c-jun-n-terminal-kinasen (jnk) und p-38-kinasen |
| US7402582B2 (en) | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| CN101535312B (zh) * | 2006-11-03 | 2013-04-24 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| US8268998B2 (en) | 2006-11-03 | 2012-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| US20120035177A1 (en) * | 2009-04-16 | 2012-02-09 | Bristol-Myers Squibb Company | Tablet formulation for p38 inhibitor and method |
| CN102971323A (zh) * | 2010-05-28 | 2013-03-13 | 拜奥克里斯特制药公司 | 作为janus激酶抑制剂的杂环化合物 |
| CN103012439B (zh) * | 2012-11-15 | 2015-03-11 | 沈阳药科大学 | 苯甲酰基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014143607A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
| WO2014143606A1 (en) * | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2015054358A1 (en) | 2013-10-11 | 2015-04-16 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| AU2018346709A1 (en) | 2017-10-05 | 2020-04-16 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CN108516977A (zh) * | 2018-07-10 | 2018-09-11 | 刘凤娟 | 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法 |
| CN112028892B (zh) * | 2020-07-29 | 2022-12-16 | 天津全和诚科技有限责任公司 | 4-氨基-吡咯并三嗪衍生物在制备抗肺纤维化制剂中的应用 |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| KR20250007533A (ko) | 2022-04-08 | 2025-01-14 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, ras질환 및 섬유성 질환의 치료를 위한 ras 슈퍼패밀리 단백질과 상호작용하는 화합물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163399A1 (en) * | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
| WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| JP4649046B2 (ja) * | 1999-05-21 | 2011-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼのピロロトリアジン阻害剤 |
-
2001
- 2001-11-07 HR HR20030485A patent/HRP20030485A2/hr not_active Application Discontinuation
- 2001-11-07 JP JP2002543494A patent/JP2004522713A/ja active Pending
- 2001-11-07 CA CA002429628A patent/CA2429628A1/en not_active Abandoned
- 2001-11-07 CZ CZ20031370A patent/CZ20031370A3/cs unknown
- 2001-11-07 DK DK01992298T patent/DK1363910T3/da active
- 2001-11-07 KR KR1020037006661A patent/KR100847605B1/ko not_active Expired - Fee Related
- 2001-11-07 PL PL01366376A patent/PL366376A1/xx not_active Application Discontinuation
- 2001-11-07 CN CNA018189970A patent/CN1622946A/zh active Pending
- 2001-11-07 AU AU2002232760A patent/AU2002232760B2/en not_active Ceased
- 2001-11-07 EP EP01992298A patent/EP1363910B1/en not_active Expired - Lifetime
- 2001-11-07 IL IL15557001A patent/IL155570A0/xx unknown
- 2001-11-07 SK SK540-2003A patent/SK5402003A3/sk unknown
- 2001-11-07 PT PT01992298T patent/PT1363910E/pt unknown
- 2001-11-07 BR BR0115446-0A patent/BR0115446A/pt not_active IP Right Cessation
- 2001-11-07 MX MXPA03004290A patent/MXPA03004290A/es active IP Right Grant
- 2001-11-07 ES ES01992298T patent/ES2259051T3/es not_active Expired - Lifetime
- 2001-11-07 EE EEP200300227A patent/EE200300227A/xx unknown
- 2001-11-07 NZ NZ525334A patent/NZ525334A/en unknown
- 2001-11-07 DE DE60117607T patent/DE60117607T2/de not_active Expired - Lifetime
- 2001-11-07 WO PCT/US2001/049982 patent/WO2002040486A2/en not_active Ceased
- 2001-11-07 AT AT01992298T patent/ATE318820T1/de not_active IP Right Cessation
- 2001-11-07 GE GE5243A patent/GEP20063915B/en unknown
- 2001-11-07 HU HU0303897A patent/HUP0303897A2/hu unknown
- 2001-11-07 YU YU37903A patent/YU37903A/sh unknown
- 2001-11-07 AU AU3276002A patent/AU3276002A/xx active Pending
- 2001-11-13 MY MYPI20015207A patent/MY127066A/en unknown
- 2001-11-16 PE PE2001001141A patent/PE20020819A1/es not_active Application Discontinuation
- 2001-11-16 AR ARP010105381A patent/AR032637A1/es unknown
-
2003
- 2003-04-21 BG BG107750A patent/BG107750A/bg unknown
- 2003-05-14 IS IS6816A patent/IS6816A/is unknown
- 2003-05-16 NO NO20032229A patent/NO20032229L/no not_active Application Discontinuation
-
2006
- 2006-06-01 CY CY20061100698T patent/CY1105250T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032229D0 (no) | Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer | |
| NO20015650L (no) | Pyrrolotriazin-inhibitorer for kinaser | |
| NO20021239D0 (no) | Pteridinoner som kinase-inhibitorer | |
| DK1140840T3 (da) | omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer | |
| NO20030241D0 (no) | Fremgangsmåte for behandling av multiple brönnintervaller | |
| NO20026010L (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
| NO20021329D0 (no) | Kinaseinhibitorer som terapeutiske midler | |
| DK2253620T3 (da) | Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer | |
| NO20021820L (no) | Tyrosinkinaseinhibitorer | |
| NO20030135D0 (no) | Piperidinforbindelser for bruk som CCR-3 inhibitorer | |
| NO20015065D0 (no) | Pyrazolobenzodiazepiner som CDK2-inhibitorer | |
| NO20031191D0 (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
| NO20032670D0 (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
| DK0950657T3 (da) | Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer | |
| PT1171440E (pt) | 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| NO20042938L (no) | Nitrogenholdige forbindelser som korrosjonsinhibitorer | |
| FI20012170L (fi) | Menetelmä lauhteiden käsittelemiseksi | |
| DK1690853T3 (da) | Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer | |
| IDP000027420A (id) | Inhibitor-inhibitor kinase pirolotriazin | |
| IT1315938B1 (it) | Procedimento per trattare superfici esposte di spazi chiusi. | |
| DK1296981T3 (da) | Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer | |
| EE9900117A (et) | Meetod nitriti kolorimeetriliseks määramiseks | |
| DK1317448T4 (da) | Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |